Results 81 to 90 of about 1,677,383 (218)

The role of the cytoskeleton in fibrotic diseases

Frontiers in Cell and Developmental Biology
Fibrosis is the process whereby cells at a damaged site are transformed into fibrotic tissue, comprising fibroblasts and an extracellular matrix rich in collagen and fibronectin, following damage to organs or tissues that exceeds their repair capacity ...
Caoyuan Niu, Yanan Hu, Kai Xu, Xiaoyue Pan, Lan Wang, Guoying Yu   +5 more
doaj   +1 more source

Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study

BMC Pulmonary Medicine
Background This study aimed to investigate longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) on high-resolution computed tomography (HRCT).
Yuhui Qiang, Hongyi Wang, Yifei Ni, Jianping Wang, Anqi Liu, Jie Du, Linfeng Xi, Yinan Hu, Yanhong Ren, Bingbing Xie, Shiyao Wang, Jing Geng, Min Liu, Huaping Dai   +13 more
doaj   +1 more source

Antifibrotic drugs for idiopathic pulmonary fibrosis

, 2020
Vijay Hadda, Randeep Guleria
openalex   +1 more source

Activation of somatostatin receptors attenuates pulmonary fibrosis [PDF]

, 2007
Raphaël Borie, Aurélie Fabre, Fabienne Prost, J. Marchal-Sommé, Rachida Lebtahi, S. Marchand‐Adam, Michel Aubier, P Soler, Bruno Crestani   +8 more
openalex   +1 more source

Pulmonary Fibrosis caused by Asbestos Fibers in the Respiratory Airway

, 2021
Ji-Woo Jung, Eung‐Sam Kim
openalex   +2 more sources

Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) [PDF]

, 2009
Ganesh Raghu, Talmadge E. King, Jürgen Behr, Kevin K. Brown, R M du Bois, Isabelle Leconte, Sébastiên Roux, Jeffrey J. Swigris   +7 more
openalex   +1 more source

A Randomized Controlled Trial of the Safety and Efficacy of Systemic Enzyme Supplementation on Symptoms and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis

Diseases
Idiopathic pulmonary fibrosis (IPF) imposes a substantial symptom burden that adversely impacts patients’ quality of life. Current anti-fibrotic treatments for IPF provide limited symptomatic relief, necessitating the implementation of complementary ...
Neha Shah
doaj   +1 more source

Potential effects of hydroxysafflor yellow A on reducing pulmonary inflammation and fibrosis due to SARS-COV2

, 2022
Ami Febriza, Vivien novarina a Kasim
openalex   +2 more sources

Idiopathic pulmonary fibrosis.

Nursing Standard, 2014
S. Rosselot
semanticscholar   +1 more source

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

The Lancet Respiratory Medicine, 2020
Peter M. George, A. Wells, R. G. Jenkins
semanticscholar   +1 more source